Both treated and untreated tumors are eliminated by short hairpin RNA-based induction of target-specific immune responses

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 20, 2009, Pages 8314-8319

  Gu, Wenyi ^a   Cochrane, Melanie ^a   Leggatt, Graham R ^a   Payne, Elizabeth ^a   Choyce, Allison ^a   Zhou, Fang ^a   Tindle, Robert ^a   McMillan, Nigel A J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antigen presentation; Cancer; CTL epitope; RNAi

Indexed keywords

EPITOPE; GAMMA INTERFERON; LENTIVIRUS VECTOR; MESSENGER RNA; OVALBUMIN; PROTEIN E6; PROTEIN E7; RNA INDUCED SILENCING COMPLEX; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CANCER GENE THERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA CLEAVAGE; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNE RESPONSE GENE; INOCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RNA INTERFERENCE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIGENS, NEOPLASM; EPITOPES; HUMANS; HYDROLYSIS; IMMUNITY; MICE; NEOPLASMS, EXPERIMENTAL; RNA, MESSENGER; RNA, SMALL INTERFERING; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION;

ANIMALIA; MUS;

EID: 66249094201     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0812085106     Document Type: Article

References (35)

1. Nguyen T, Menocal EM, Harborth J, Fruehauf JH (2008) RNAI therapeutics: An update on delivery, Curr Opin Mol Ther 10:158-167.
2. Stallwood Y, et al. (2006) Small Interfering RNA-medlated knockdown of notch llgands in primary CD4+ T cells and dendritic cells enhances cytokine production, J Immunol 177:885-895.
3. HIll JA, et al. (2003) immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA, J Immunol 171:691-696.
4. Hornung V, et al. (2005) Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytold dendritic cells through TLR7, Nat Med 11:263-270.
5. Judge AD, et al. (2005) Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA, Nat Biotechnol 23:457-462.
6. Poeck H, et al. (2008) 5'-Trlphosphate-siRNA: Turning gene silencing and RIg-1 activation against melanoma, Nat Med 14:1256-1263.
7. Sledz CA, Williams BR (2004) RNA interference and double-stranded-RNA- actlvated pathways, Biochem Soc Trans 32:952-956.
8. Marques JT, et al. (2006) A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells, Nat Biotechnol 24:559-565.
9. Gantier MP, Williams BR (2007) The response of mammalian cells to double-stranded RNA, Cytokine Growth Factor Rev 18:363-371.
10. Chen W, et al. (2004) Reversal in the lmmunodomlnance hierarchy in secondary CD8+ T cell responses to influenza A virus: Roles for cross-presentation and lysis-independent immunodomination, J Immunol 173:5021-5027.
11. Esquivei F, Yewdell J, Bennink J (1992) RMA/S cells present endogenously synthesized cytosolic proteins to class l-restricted cytotoxic T lymphocytes, J Exp Med 175:163-168.
12. Qian SB, et al. (2006) Tight linkage between translation and MHC class 1 peptide llgand generation implies specialized antigen processing for defective rlbosomal products, J Immunol 177:227-233.
13. Yewdell JW, Anton LC, Bennink JR (1996) Defective rlbosomal products (DRIPs): a major source of antigenic peptides for MHC class I molecules? J Immunol 157:1823-1826.
14. Yewdell JW, Nicchitta CV (2006) The DRIP hypothesis decennial: Support, controversy, refinement and extension, Trends Immunol 27:368-373.
15. Lin KY, et al. (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen, Cancer Res 56:21-26.
16. Gu W, et al. (2006) inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes, Cancer Gene Ther 13:1023-1032.
17. Feltkamp MC, et al. (1993) Vaccination with cytotoxic Tlymphocyte epltope-contalnlng peptide protects against a tumor induced by human papillomavirus type 16transformed cells Eur J Immunol 23:2242-2249.
18. Khammanivong V, et al. (2003) Paucity of functional CTL epitopes in the E7 oncoprotein of cervical cancer associated human papillomavirus type 16 Immunol Cell Biol 81:1-7.
19. XueW, et al. (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas, Nature 445:656-660.
20. Nowak AK, et al. (2003) induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerlzlng host tumorspecific CD8 T cells, J Immunol 170:4905-4913.
21. Lelouard H, et al. (2004) Dendritic cell aggresome-like induced structures are dedicated areasfor ubiquitination and storage of newly synthesized defective proteins, J Cell Biol 164:667-675.
22. Tindle RW, et al. (1995) A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants, Clin Exp Immunol 101:265-271.
23. Zamore PD,Tuschl T, Sharp PA, Bartel DP (2000) RNAi: Double-stranded RNAdlrectsthe ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals, Cell 101:25-33.
24. Orban Ti, izaurralde E (2005) Decay of mRNAs targeted by RISC requires XRN1, the Ski complex, and the exosome, Rna 11:459-469.
25. Elbashlr SM, Lendeckel W, Tuschl T (2001) RNA interference is mediated by 21- and 22-nudeotlde RNAs, Genes Dev 15:188-200.
26. Nykanen A, Haley B, Zamore PD (2001) ATP requirements and small interfering RNA structure in the RNA interference pathway, Cell 107:309-321.
27. Martinez J, Tuschl T (2004) RISC is a 5' phosphomonoester-produclng RNA endonuclease, Genes Dev 18:975-980.
28. Schwarz DS, Tomarl Y, Zamore PD (2004) The RNA-induced silencing complex is a Mg2- -dependent endonuclease, CurrBiol 14:787-791.
29. Beilharz TH, Preiss T (2007) Widespread use of poly(A) tall length control to accentuate expression of the yeast transcrlptome, RNA 13:982-997.
30. Ripberger E, Linnebacher M, Schwltalle Y, Gebert J, von Knebel Doeberltz M (2003) identification of an HLA-A0201 -restricted CTL epitope generated by a tumor-speclflc frameshlft mutation in a coding microsatelllte of the OGT gene, J Clin Immunol 23:415-423.
31. Schwitalle Y, Linnebacher M, Rlpberger E, Gebert J, von Knebel Doeberitz M (2004) Immunogenic peptides generated by frameshift mutations in DNA mismatch repairdeficient cancer cells, Cancer Immun 4:14.
32. Moore MW, Carbone FR, Bevan MJ (1988) introduction of soluble protein Into the class I pathway of antigen processing and presentation, Cell 54:777-785.
33. Matsumoto K, et al. (2004) impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors, J Natl Cancer Inst 96:16111619.
34. LeTT, et al. (2001) Cytotoxic T cell polyepltope vaccines delivered by ISCOMs, Vaccine 19:4669-4675.
35. Doan T, et al. (1998) Mice expressing the E7 oncogene of HPV16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic T-lymphocyte epitopes, Virology 244:352-364.